选择性激光小梁成形术对眼压控制与视野进展的长期结局
该回顾性病例对照研究纳入2002至2021年间接受SLT的500眼(500例患者),平均随访9.6年,评估SLT后眼压控制失败时间及5年视野进展。首次SLT失败中位时间4.6年,重复SLT为2.7年;重复SLT、既往青光眼手术、哮喘及中晚期青光眼与失败风险升高相关,较高能量强度与较低风险相关。5年视野进展与术前用药、较高能量强度及较低中央角膜厚度相关。
要点
- 首次SLT失败中位时间4.6年,重复SLT为2.7年。
- 重复SLT、既往青光眼手术、哮喘及中晚期青光眼与失败风险升高相关。
- 较高能量强度与失败风险降低相关,但亦与5年视野进展风险升高相关。
核心结论
- 重复SLT、哮喘、既往青光眼手术、更晚期青光眼或较低激光能量强度者结局较差。
- 术前用药负担较高和角膜厚度较低与5年视野进展风险较高相关。
研究设计与样本
- 回顾性病例对照研究,纳入2002至2021年间接受SLT的500眼(500例患者),平均随访9.6年,要求至少5年随访及4次可靠视野检查。
- 采用Kaplan-Meier生存分析和多因素Cox回归评估治疗失败时间,多因素logistic回归识别5年视野进展预测因素。
主要发现
- 首次SLT失败中位时间4.6年,重复SLT为2.7年。
- 多因素分析中,重复SLT(HR 1.49,P = .008)、既往青光眼手术(HR 2.33,P < .001)、哮喘(HR 1.40,P = .032)及中晚期青光眼(HR 1.54,P < .001)与失败风险升高相关,较高能量强度与较低风险相关(HR 0.91,P < .001)。
- 在302眼有足够视野数据者中,5年视野进展与术前用药(OR 1.57,P = .006)、较高能量强度(OR 1.48,P = .004)及较低中央角膜厚度(OR 0.90,P = .028)相关。
关键数值与推荐
- 治疗失败定义为未达到≥20%眼压降幅或眼压≥21 mmHg、需要升级用药或额外青光眼手术。
- 视野进展定义为SLT后5年时三种方法(平均偏差斜率、点wise线性回归和青光眼速率指数)中至少2种一致显示进展。
临床怎么用
- 这些发现可帮助识别SLT长期结局较差的患者,如重复SLT、哮喘、既往青光眼手术或更晚期青光眼者。
- 术前用药负担较高和角膜厚度较低者可能需更密切的SLT后视野监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the long-term outcomes of selective laser trabeculoplasty (SLT) on intraocular pressure (IOP) control and visual field (VF) progression, and to identify factors associated with them. DESIGN: Retrospective case-control study. SUBJECTS, PARTICIPANTS, AND/OR CONTROLS: A total of 500 eyes from 500 patients who underwent SLT between 2002 and 2021, with a mean follow-up of 9.6 years. Inclusion required at least 5 years of follow-up and 4 reliable perimetry examinations for VF analysis. METHODS: Kaplan-Meier survival analysis and multivariable Cox regression were used to evaluate time to treatment failure, defined as failure to achieve ≥20% IOP reduction or IOP ≥21 mmHg, need for medication escalation, or additional glaucoma surgery. Multivariable logistic regression was used to identify predictors of VF progression, defined by concordant progression on at least 2 of 3 methods (mean deviation slope, pointwise linear regression, and glaucoma rate index) at 5 years after SLT. MAIN OUTCOME MEASURES: Time to IOP-based treatment failure and VF progression at 5 years after SLT. RESULTS: Median time to failure was 4.6 years for initial SLT and 2.7 years for repeat SLT. In multivariable analysis, repeat SLT (HR 1.49, P = .008), prior glaucoma surgery (HR 2.33, P < .001), asthma (HR 1.40, P = .032), and moderate-to-advanced glaucoma (HR 1.54, P < .001) were associated with a higher risk of failure, whereas higher energy intensity was associated with a lower risk (HR 0.91, P < .001). Among 302 eyes with sufficient VF data, VF progression at 5 years was associated with pre-SLT medications (OR 1.57, P = .006), higher energy intensity (OR 1.48, P = .004), and lower central corneal thickness (OR 0.90, P = .028). CONCLUSIONS: Outcomes were less favorable in eyes undergoing repeat SLT, with asthma, prior glaucoma surgery, more advanced disease, or lower laser energy intensity. Higher pre-SLT medication burden and lower corneal thickness were associated with a greater risk of VF progression. These findings identify clinical and treatment-related factors associated with long-term SLT outcomes and may help inform patient selection and post-SLT monitoring.
引用
- Lee K, Morales E, Caprioli J, et al. Long-Term Outcomes of Selective Laser Trabeculoplasty on Intraocular Pressure Control and Visual Field Progression. Am J Ophthalmol. 2026. PMID: 42586189. doi:10.1016/j.ajo.2026.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。